Cancer Vaccines in Ovarian Cancer: How Can We Improve?
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2016-05-03 / Biomedicines 2016 May;4(2)A study of mature alpha-DC-1 vaccine to induce immune responses in ovarian cancer.
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2015-05-29 / J Clin Oncol 33, 2015 (suppl; abstr e14033)Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2015-02-26 / Gynecol. Oncol. 2015 May;137(2):335-42[The effect of immunotherapy and hyperthermia on advanced or recurrent ovarian and uterine cancer – 229 clinical cases]
/in Endometrial Cancer, International Publications, Ovarian Cancer /von 2014-10-01 / Gan To Kagaku Ryoho 2014 Oct;41(10):1295-7Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2014-06-30 / Cell. Mol. Immunol. 2015 Jan;12(1):87-95Ovarian cancer biology and immunotherapy
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2014-06-09 / Int. Rev. Immunol. 2014 Oct;33(5):428-40Autologous dendritic cell vaccination (DCVAC/OvCa) added to standard of care therapy in three open-label randomized phase 2 studies in women with advanced stage ovarian cancer (OC).
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3134)The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2014-05-07 / J Ovarian Res 2014 May;7:48Wilms‘ tumor gene 1 immunotherapy in pelvic gynecological malignancies
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Ovarian Cancer, Uterine Cancer /von 2014-05-02 / Expert Rev Clin Immunol 2014 Jun;10(6):705-11
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus
- Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
- A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma